Copyright © 2006 American Chemical Society
 

June 19, 2006 Issue

Volume 84, Issue 25
8425introimg1
June 19, 2006 Issue, Vol. 84 | Iss. 25

An Industry In Transition

C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
By A. Maureen Rouhi
(pp. 24-28)
Features
Science & Technology

Triple Cascade

Asymmetric reaction constructs three new C-C bonds and four stereocenters (p.13)
Business

Pharma In Flux

Fundamental changes erupt across the industry as companies strive to improve drug efficacy and safety and R&D efficiency in the face of negative public opinion (pp. 30-55)
Back Issues
 

News of the Week

Triple Cascade

Asymmetric reaction constructs three new C-C bonds and four stereocenters
(p.13)

Georgia Gulf Will Buy Royal Group

Deal will create a large, back-integrated vinyl products supplier
(p.14)

Greener Cleaners

EPA initiative urging phaseout of NPE surfactants receives mixed reviews
(p.14)

Aging Cells Get New Lease On Life

Small molecule is found to extend lifetime of mammalian cells
(p.15)

Schering Shares

Merck's threat to derail Bayer's acquisition of Schering is resolved
(p.15)

Herzenberg Nabs Kyoto Prize

Award honors the developer of the fluorescence-activated cell sorter
(p.16)
 

Departments

8425pharma1_paulacxd1

Business

Patient Activism

Researchers Are Admonished To Stay Focused
(pp. 42-43)

Accounting For R&D

Many Doubt The $800 Million Pharmaceutical Price Tag
(p.50)

Pharma In Flux

Fundamental changes erupt across the industry as companies strive to improve drug efficacy and safety and R&D efficiency in the face of negative public opinion
(pp. 30-55)

An Industry In Transition

C&EN examines how the pharmaceutical industry, now on the defensive, is trying to win back the public's confidence and enhance productivity
(pp. 24-28)
8425pharma3_box1cxd

Government & Policy

Prescription For Chaos

For Most Retirees, Medicare Program Fails To Lower Costs
(pp. 84-85)

Affordable Medicine

Citing Application Backlog, Makers Of Generic Drugs Seek To Boost FDA Funding
(p.92)

Regulatory Trends

Strong action on drug safety and pricing is more likely to come from states than from Congress or FDA
(pp. 80-99)

Effective Manufacturing

FDA Process Guidelines Encourage Efficient Plant Controls
(p.66)

Science & Technology

Improving Efficiency

To eliminate R&D bottlenecks, drug companies are evaluating all phases of discovery and development and are using novel approaches to speed them up
(pp. 56-78)

Newscripts

Dreadful research, The early bird catches the caterpillar, Fixing air 250 years ago

(p.120)

Editor's Page

Focus On Pharma

(p.5)

Letters